High dose radioimmunotherapy in relapsed B-cell lymphoma with I-131 rituximab

Role of p38 mitogen-activated protein kinase in cardiac remodelling.

British journal of pharmacology·2006

[Guideline for radioimmunotherapy of rituximab relapsed or refractory CD20(+) follicular B-cell non-Hodgkin's lymphoma].

Nuklearmedizin. Nuclear medicine·2004

Endoscopic sentinel lymphadenectomy as a new diagnostic approach in the N0 neck.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·2004

Endosonographic imaging of benign and malignant pheochromocytomas.

The Journal of clinical endocrinology and metabolism·2004

Biodistribution, blood half-life, and receptor binding of a somatostatin-dextran conjugate.

Medical oncology (Northwood, London, England)·2002

Value of sentinel lymphonodectomy in head and neck cancer patients without evidence of lymphogenic metastatic disease.

Auris, nasus, larynx·2001

Outcomes of down syndrome-related myeloid leukemia in Turkiye: a multicenter retrospective observational cohort study by the Turkish Pediatric Hematology Association.

Annals of hematology·2026

Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma.

Annals of hematology·2026

Chidamide plus venetoclax as effective and safe maintenance therapy in high-risk acute myeloid leukemia and myelodysplastic syndrome post-transplantation.

Annals of hematology·2026

Optimizing venetoclax duration with hypomethylating agents for newly diagnosed acute myeloid leukemia: impact on response and survival.

Annals of hematology·2026

Defining and managing high-risk acute myeloid leukemia (AML) in 2026.

Annals of hematology·2026

Durable CNS remission with elranatamab and intrathecal therapy in relapsed/refractory multiple myeloma.

Annals of hematology·2026

Targeting METTL3/m6A/SOCS3 axis reprograms tumor-associated macrophage polarization to potentiate the efficacy of anti-PD-1 therapy in multiple myeloma.

Cellular and molecular life sciences : CMLS·2026

Distinct clinical and immunologic patterns of interferon-γ release assays: implications for indeterminate results and sequential testing strategies.

Microbiology spectrum·2026

Recalcitrant Infectious Keratitis in DOCK8 Immunodeficiency Syndrome.

Journal of pediatric ophthalmology and strabismus·2026

Early but not serial ustekinumab concentration measurements are associated with clinical outcomes in Crohn's disease and ulcerative colitis: the Stockholm Ustekinumab study (STOCUSTE).

European journal of gastroenterology & hepatology·2026

Cost comparison of intravenous immunoglobulin and subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyneuropathy.

Journal of medical economics·2026

Head-to-head comparison of [18F]AlF-NOTA-JR11 PET/MR and [68Ga]Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors.

European journal of nuclear medicine and molecular imaging·2026

Related Experiment Videos

High dose radioimmunotherapy in relapsed B-cell lymphoma with I-131 rituximab

Related Concept Videos

Role of p38 mitogen-activated protein kinase in cardiac remodelling.

[Guideline for radioimmunotherapy of rituximab relapsed or refractory CD20(+) follicular B-cell non-Hodgkin's lymphoma].

Endoscopic sentinel lymphadenectomy as a new diagnostic approach in the N0 neck.

Endosonographic imaging of benign and malignant pheochromocytomas.

Biodistribution, blood half-life, and receptor binding of a somatostatin-dextran conjugate.

Value of sentinel lymphonodectomy in head and neck cancer patients without evidence of lymphogenic metastatic disease.

Outcomes of down syndrome-related myeloid leukemia in Turkiye: a multicenter retrospective observational cohort study by the Turkish Pediatric Hematology Association.

Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma.

Chidamide plus venetoclax as effective and safe maintenance therapy in high-risk acute myeloid leukemia and myelodysplastic syndrome post-transplantation.

Optimizing venetoclax duration with hypomethylating agents for newly diagnosed acute myeloid leukemia: impact on response and survival.

Defining and managing high-risk acute myeloid leukemia (AML) in 2026.

Durable CNS remission with elranatamab and intrathecal therapy in relapsed/refractory multiple myeloma.

Targeting METTL3/m6A/SOCS3 axis reprograms tumor-associated macrophage polarization to potentiate the efficacy of anti-PD-1 therapy in multiple myeloma.

Distinct clinical and immunologic patterns of interferon-γ release assays: implications for indeterminate results and sequential testing strategies.

Recalcitrant Infectious Keratitis in DOCK8 Immunodeficiency Syndrome.

Early but not serial ustekinumab concentration measurements are associated with clinical outcomes in Crohn's disease and ulcerative colitis: the Stockholm Ustekinumab study (STOCUSTE).

Cost comparison of intravenous immunoglobulin and subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyneuropathy.

Head-to-head comparison of [18F]AlF-NOTA-JR11 PET/MR and [68Ga]Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors.

Related Experiment Videos

High dose radioimmunotherapy in relapsed B-cell lymphoma with I-131 rituximab

Related Concept Videos

Related Articles